Prostate cancer charity highlights Lancet article

22 December 2008

The UK Prostate Cancer Charity has highlighted an article to be published in The Lancet, which claims that combining radiotherapy with hormone therapy treatment halves mortality in men with locally-advanced prostate cancer.

Chief executive John Neate said: "although prostate cancer specialists will have to digest all the results of this significant study before any changes feed into medical care, it does seem to represent real progress in treatment for men with locally advanced prostate cancer - where the cancer has spread just outside the prostate gland."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight